The Preclinical Design and Clinical Translation of TB Regimens (PReDicTR) Consortium has been awarded a $30.8M grant over five years to research the most effective treatment options for future clinical testing.
School researchers netted $36.7M from 65 grants, fueling efforts spanning drug discovery, bioengineering, pharmacokinetics, clinical pharmacy, and more.
The first program of its kind in the United States, the MS in AICD3 will enable its graduates to gain a competitive edge for some of the most desirable jobs in the biopharmaceutical industry and in academia.
